ARTICLE | Clinical News
NovoVAC-M1: Began Phase I/II trial
June 21, 1999 7:00 AM UTC
Novopharm Biotech Inc. (TSE:NVO), Toronto, Ontario Product: NovoVAC-M1 Business: Cancer Therapeutic category: Antibody, Immune stimulation Target: GD2 melanoma antigen Description: Human antibody vacc...